Search

Displaying results 1941 - 1950 of 7687 in total
  1. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]

  2. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.

  3. Drug

    Filgrastim

    go.drugbank.com/drugs/DB00099
    ApprovedInvestigational

    It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. … [A245858] Tbo-filgrastim was approved by the FDA on August 29, 2012.[L36325] Filgrastim-sndz was approved on March 6, 2015 [L40768] and filgrastim-ayow was approved on March 2, 2022.

    Products: ZARZIO (30 MU), NEUPOGEN (30 MU)
  4. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. … The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis.

  5. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births

  6. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid . It has been used for stimulation of biliary lipid secretion. The use of dehydrocholic acid in over-the-counter products h...

  7. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]

  8. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.

  9. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]

  10. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition.